Effect of GLP-1 Agonist Therapy on Insulin Secretion in Adults with Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a randomized, open-label, cross-over trial
The purpose of this research study is to examine and understand the various mechanisms that contribute to CFRD and gain a better understanding of possible ways to treat CFRD.
Why this Research Matters
This research is being done to better understand Cystic-Fibrosis Related Diabetes (CFRD) and to see the effects of GLP-1 (dulaglutide) in individuals with abnormal glucose tolerance. GLP-1 (dulaglutide) helps the pancreas release insulin, which controls blood sugar levels from getting too high and is currently prescribed to people with Type 2 diabetes. We are looking at how GLP-1 (dulaglutide) might help improve blood sugar levels for people with CF and abnormal glucose tolerance.
Who can Participate
Male or female, aged 18 or older at time of consent; confirmed diagnosis of CF; pancreatic insufficiency; and abnormal glucose tolerance. Stated willingness to comply with all study procedures and availability for the duration of the study; ability to take subcutaneous medication and be willing to adhere to the weekly administration regimen and complete study specific procedures (MMTT-mixed meal tolerance test); for females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 weeks after the end of dulaglutide or observation.
Study ID
Protocol Number: 23-1267
Meet the Team
Principal Investigator